Desmopressin in treatment of haematological disorders and in prevention of surgical bleeding

Blood Reviews

Volumn 28, Issue 3, 2014, Pages 95-102

  Svensson, Peter J ^a   Bergqvist, Peter B F ^b   Juul, Kristian Vinter ^b   Berntorp, Erik ^a  

^a LUND UNIVERSITY   (Sweden)

^b Ferring Pharmaceuticals AS   (Denmark)

Author keywords

Desmopressin; Haematological disorders; Haemophilia; Surgical bleeding; Von Willebrand disease

Indexed keywords

DESMOPRESSIN; PLACEBO; ARGIPRESSIN[1 DEAMINO];

ARTICLE; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HEMATOLOGIC DISEASE; HEMOPHILIA; HUMAN; HYPONATREMIA; LIVER CIRRHOSIS; OPERATIVE BLOOD LOSS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOCYTE DYSFUNCTION; THROMBOCYTE FUNCTION; UNSPECIFIED SIDE EFFECT; UREMIA; VON WILLEBRAND DISEASE; BLOOD LOSS, SURGICAL; HEMATOLOGIC DISEASES;

BLOOD LOSS, SURGICAL; DEAMINO ARGININE VASOPRESSIN; HEMATOLOGIC DISEASES; HUMANS;

EID: 84900849295     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2014.03.001     Document Type: Article

References (72)

1. Kaufmann J.E., Iezzi M., Vischer U.M. Desmopressin (DDAVP) induces NO production in human endothelial cells via V2 receptor- and cAMP-mediated signaling. J Thromb Haemost Apr 2003, 1(4):821-828.
2. Medina P., Segarra G., Vila J.M., Chuan P., Domenech C., Lluch S. V2-receptor-mediated relaxation of human renal arteries in response to desmopressin. Am J Hypertens Feb 1999, 12(2 Pt 1):188-193.
3. Kaufmann J.E., Oksche A., Wollheim C.B., Günther G., Rosenthal W., Vischer U.M. Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. J Clin Invest Jul 2000, 106(1):107-116.
4. Schulman S. DDAVP - the multipotent drug in patients with coagulopathies. Transfus Med Rev 1991, 5:132-144.
5. Datta Y.H., Ewenstein B.M. Regulated secretion in endothelial cells: biology and clinical implications. Thromb Haemost 2001, 86:1148-1155.
6. Frenette P.S., Johnson R.C., Hynes R.O., Wagner D.D. Platelets roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin. Proc Natl Acad Sci U S A 1995, 92:7450-7454.
7. Calmer S., Ferkau A., Larmann J., Johanning K., Czaja E., Hagl C., et al. Desmopressin (DDAVP) improves recruitment of activated platelets to collagen but simultaneously increases platelet endothelial interactions in vitro. Platelets 2014, 25(1):8-15.
8. Lethagen S., Harris A.S., Sjörin E., Nilsson I.M. Intranasal and intravenous administration of desmopressin: effect on F VIII/vWF, pharmacokinetics and reproducibility. Thromb Haemost Dec 18 1987, 58(4):1033-1036.
9. De la Fuente B., Kasper C.K., Rickles F.R., Hoyer L.W. Response of patients with mild and moderate hemophilia A and von Willebrand's disease to treatment with desmopressin. Ann Intern Med 1985, 103(1):6-14.
10. Mannucci P.M. Desmopressin: a nontransfusional form of treatment for congenital and acquired bleeding disorders. Blood 1988, 72(5):1449-1455.
11. Schulman S. DDAVP-the multipotent drug in patients with coagulopathies. Transfus Med Rev 1991, 5(2):132-144.
12. Mannucci P.M., Åberg M., Nilsson I.M., Robertson B. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol 1975, 30:81-93.
13. Lassila R., Holme P.A., Landorph A., Petrini P., Onundarson P.T., Hillarp A. Nordic Haemophilia Council's practical guidelines on diagnosis and management of von Willebrand disease. Semin Thromb Hemost Jul 2011, 37(5):495-502. [Epub 2011 Nov 18. Review]. 10.1055/s-0031-1281034.
14. Mannucci P.M. Treatment of von Willebrand's disease. N Engl J Med 2004, 351(7):683-694.
15. Mannucci P.M. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20years. Blood 1997, 90(7):2515-2521.
16. Lethagen S., Schulman S., Tengborn L. Desmopressin-an effective agent in many hemorrhagic disorders. Lakartidningen 1992, 89(48):4155-4158.
17. Flordal P.A., Sahlin S. Use of desmopressin to prevent bleeding complications in patients treated with aspirin. Br J Surg 1993, 80(6):723-724.
18. Steinlechner B., Zeidler P., Base E., Birkenberg B., Ankersmit H.J., Spannagl M., et al. Patients with severe aortic valve stenosis and impaired platelet function benefit from preoperative desmopressin infusion. Ann Thorac Surg 2011, 91(5):1420-1426.
19. Mariana G., Ciavarella N., Mazzucconi M.G., Antoncecchi S., Solinas S., Ranieri P., et al. Evaluation of the effectiveness of DDAVP in surgery and bleeding episodes in haemophilia and von Willebrand's disease. A study on 43 patients. Clin Lab Haematol 1984, 6:229-238.
20. Mannucci P.M. Desmopressin (DDAVP) for treatment of disorders of hemostasis. Prog Hemost Thromb 1986, 8:19-45.
21. Lethagen S. Desmopressin (DDAVP) and hemostasis. Ann Hematol 1994, 69(4):173-180.
22. Manning M., Stoev S., Chini B., Durroux T., Mouillac B., Guillon G. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog Brain Res 2008, 170:473-512.
23. Castaman G., Lethagen S., Federici A.B.., Tosetto A., Goodeve A., Budde U., et al. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood Apr 1 2008, 111(7):3531-3539.
24. Federici A.B.., Mazurier C., Berntorp E., Lee C.A., Scharrer I., Goudemand J., et al. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood Mar 15 2004, 103(6):2032-2038.
25. Castaman G., Tosetto A., Rodeghiero F. Reduced von Willebrand factor survival in von Willebrand disease: pathophysiologic and clinical relevance. J Thromb Haemost Jul 2009, 7(Suppl. 1):71-74.
26. Schulman S. Desmopressin injection 15μg/mL for subcutaneous administration in testing of patients with von Willebrand's disease and platelet dysfunction. Ferring internal report 45A05/PR/79 1989.
27. Kobrinsky N.L., Israels E.D., Gerrard J.M., Cheang M.S., Watson C.M., Bishop A.J., et al. Shortening of bleeding time by 1-deamino-8-d-arginine vasopressin in various bleeding disorders. Lancet 1984, 1:1145-1148.
28. Tengborn L., Rugarn P., Stigendal L. Subcutaneous administration of desmopressin shortens the prolonged bleeding time in patients with von Willebrand's desease and platelet functional defects. Ferring internal report 45A05/PR/91 1989.
29. Franchini M. The use of desmopressin as a hemostatic agent: a concise review. Am J Hematol Aug. 2007, 82(8):731-735.
30. Köhler M., Hellstern P., Reiter B., Von Blohn G., Wenzel E. The subcutaneous administration of the vasopressin analogue 1-desamino-8-d-arginine vasopressin in patients with von Willebrand's disease and hemophilia. Klin Wochenschr 1984, 62:543-548.
31. Nitu-Whalley I.C., Griffioen A., Harrington C., Lee C.A. Retrospective review of the management of elective surgery with desmopressin and clotting factor concentrates in patients with von Willebrand disease. Am J Hematol 2001, 66:280-284.
32. Ghirardini A., Chistolini A., Tirindelli M.C., Di Paolantonio T., Iacopino G., Mariani P., et al. Clinical evaluation of subcutaneously administered DDAVP. Thromb Res 1988, 49:363-372.
33. Mörsdorf S., Köhler M., Leipnitz G., Wenzel E. The clinical significance of different routes of desmopressin (DDAVP) administration in various bleeding disorders. Folia Haematol 1988, 115:503-507.
34. Köhler M., Hellstern P., Tarrach H., Rambauer R., Wenzel E., Jutzler G.A. Subcutaneous injection of desmopressin (DDAVP): evaluation of a new, more concentrated preparation. Haemostasis 1989, 1:38-44.
35. Mannucci P.M., Remuzzi G., Pusineri F., Lombardi R., Valsecchi C., Mecca G., et al. Deamino-8-d-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 1983, 308:8-12.
36. Viganò G.L., Mannucci P.M., Lattuada A., Harris A., Remuzzi G. Subcutaneous desmopressin (DDAVP) shortens the bleeding time in uremia. Am J Hematol 1989, 31:32-35.
37. Hedges S.J., Dehoney S.B., Hooper J.S., Amanzadeh J., Busti A.J. Evidenced-based treatment recommendations for uremic bleeding. Nat Clin Pract 2007, 3:138-153.
38. Mannucci P.M., Vicente V., Vianello L., Cattaneo M., Alberca I., Coccato M.P., et al. Controlled trial of desmopressin in liver cirrhosis and other conditions associated with a prolonged bleeding time. Blood 1986, 67:1148-1153.
39. Agnelli G., Parise P., Levi M., Cosmi B., Nenci G.G. Effects of desmopressin on hemostatis in patients with liver cirrhosis. Haemostasis 1995, 25:241-247.
40. López P., Otaso J.C., Alvarez D., Rojter S., Podestá A., Albornoz L., et al. Hemostatic and hemodynamic effects of vasopressin analogue DDAVP in patients with cirrhosis. Acta Gastroenterol Latinoam 1997, 27:59-62.
41. Burroughs A.K., Matthews K., Qadiri M., Thomas N., Kernoff P., Tuddenham E., et al. Desmopressin and bleeding time in patients with cirrhosis. Br Med J 1985, 291:1377-1381.
42. Cattaneo M., Tenconi P.M., Alberca I., Garcia V.V., Mannucci P.M. Subcutaneous desmopressin (DDAVP) shortens the prolonged bleeding time in patients with liver cirrhosis. Thromb Haemost 1990, 64:358-360.
43. de Franchis R., Arcidiacono P.G., Carpinelli L., Andreoni B., Cestari L., Brunati S., et al. Randomized controlled trial of desmopressin plus terlipressin vs. terlipressin alone for the treatment of acute variceal hemorrhage in cirrhotic patients: a multicenter, double-blind study. New Italian Endoscopic Club. Hepatology 1993, 18:1102-1107.
44. Koscielny J., Ziemer S., Radke H., Schmutzler M., Kiesewetter H., Salama S., et al. Präoperative Identifikation von Patienten mit (primären) Hämostasestörungen - Ein praktisches Konzept. Hamostaseologie 2007, 27:177-184.
45. Koscielny J., Ziemer S., von Heymann C. Patients with oral anticoagulation-bridging anticoagulation in the perioperative phase. Hamostaseologie 2009, 29(3):247-255.
46. Gogarten W., Hoffmann K., van Arken H., et al. Empfehlung für die Anwendung konventioneller und neuer Antithrombotika aus anästesiologischer Sicht. Unfallchirurg 2010, 11:908-914.
47. Koscielny J., Kiesewetter H., von Tempelhoff G.F. More on: platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006, 4(6):1426-1427. [discussion 1428-34].
48. Pfanner G., Koscielny J., Pernerstorfer T., Gutl M., Perger P., Fries D., et al. Preoperative evaluation of the bleeding history. Recommendations of the working group on perioperative coagulation of the Austrian Society for Anaesthesia, Resuscitation and Intensive Care. Anaesthesist 2007, 56(6):604-611.
49. Koscielny J., Ziemer S., Radtke H., Schmutzler M., Pruss A., Sinha P., et al. A practical concept for preoperative identification of patients with impaired primary hemostasis. Clin Appl Thromb Hemost 2004, 10(3):195-204.
50. Koscielny J., von Tempelhoff G.F., Ziemer S., Radtke H., Schmutzler M., Sinha P., et al. A practical concept for preoperative management of patients with impaired primary hemostasis. Clin Appl Thromb Hemost 2004, 10(2):155-166.
51. Ferraris V.A., Brown J.R., Despotis G.J., Hammon J.W., Reece T.B., Saha S.P., et al. Update to The Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists Blood Conservation Clinical Practice Guidelines. Ann Thorac Surg 2011, 91(2011):944-982.
52. Levi M., Eerenberg E., Kamphuisen P.W. Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. J Thromb Haemost 2011, 9(9):1705-1712.
53. Carless P.A., Stokes B.J., Moxey A.J., Henry D.A. Desmopressin use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2004, [CD001884]. 10.1002/14651858.CD001884.pub2.
54. Harris A.S. Clinical experience with desmopressin: efficacy and safety in central diabetes insipidus and other conditions. J Pediatr 1989, 114:711-718.
55. Lethagen S., Frick K., Sterner G. Antidiuretic effect of desmopressin given in hemostatic dosages to healthy volunteers. Am J Hematol Feb 1998, 57(2):153-159.
56. Martinelli I. von Willebrand factor and factor VIII as risk factors for arterial and venous thrombosis. Semin Hematol 2005, 42:49-55.
57. Köhler M., Hellstern P., Miyashita C., Von Blohn G., Wenzel E. Comparative study of intranasal, subcutaneous and intravenous administration of desamino-d-arginine vasopressin (DDAVP). Thromb Haemost 1986, 55:108-111.
58. Köhler M., Harris A. Pharmacokinetics and haematological effects of desmopressin. Eur J Clin Pharmacol 1988, 35:281-285.
59. Bengtsson B. Antidiuretic effect of desmopressin given in hemostatic dosages to healthy volunteers. Internal Ferring report 45A05-119 1998.
60. Ruzicka H., Björkman S., Lethagen S., Sterner G. Pharmacokinetics and antidiuretic effect of high-dose desmopressin in patients with chronic renal failure. Pharmacol Toxicol 2003, 92:137-142.
61. Lowe G., Pettigrew A., Middleton S., Forbes C.D., Prentice C.R.M. D.D.A.V.P. in haemophilia letter. Lancet 1977, 310:614-615.
62. Ingram G.I.C., Hilton P.J. D.D.A.V.P. in haemophilia letter. Lancet 1977, 310:721-722.
63. Bichet D.G., Razi M., Lonergan M., Arthus M.-F., Papunka V., Kortas C., et al. Hemodynamic and coagulation responses to 1-desamino8-d-arginine vasopressin in patients with congenital nephrogenic diabetes insipidus. N Engl J Med 1988, 318:881-887.
64. Williams T.D.M., Lightman S.L., Leadbeater M.J. Hormonal and cardiovascular responses to DDAVP in man. Clin Endocrinol 1986, 24:89-96.
65. Albert S.G., Salvata-Lechner V., Joist J.H. Venous thromboembolism and transient thrombocytopenia in a patient with diabetes insipidus treated with desmopressin acetate (DDAVP). Thromb Res 1988, 50:695-705.
66. Bond L., Bevan B. Myocardial infarction in a patient with hemophilia treated with DDAVP. N Engl J Med 1988, 318:121.
67. Byrnes J.J., Larcada A., Moake J.L. Thrombosis following desmopressin for uremic bleeding. Am J Hematol 1988, 28:63-65.
68. O'Brien J.R., Green P.J., Salmon G., Weir P., Colin-Jones D., Arnold M., et al. Desmopressin and myocardial infarction letter. Lancet 1989, 333:664.
69. van Dantzig J.M., Düren D.R., ten Cate J.W. Desmopressin and myocardial infarction letter. Lancet 1989, 333:664-665.
70. Sánchez-Luceros A., Meschengieser S.S., Turdó K., Arizó A., Woods A.I., Casais P., et al. Evaluation of the clinical safety of desmopressin during pregnancy in women with a low plasmatic von Willebrand factor level and bleeding history. Thromb Res 2007, 120:387-390.
71. Gojnic M., Faslagic A., Likic I., Stefanovic A., Vidakovic S., Pervulov M., et al. New approach of the treatment of von Willebrand's disease during pregnancy. Arch Gynecol Obstet 2005, 273:35-38.
72. Mannucci P.M. Use of desmopressin (DDAVP) during early pregnancy in factor VIII-deficient women. Blood 2005, 105:3382.